NNP
TVRD

Nachman Norwood & Parrott’s Tvardi Therapeutics TVRD Stock Holding History

Nachman Norwood & Parrott’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-4
Closed -$2K – 1087
2020
Q3 		$2K Buy
+4
New +$2.32K ﹤0.01% 1120

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Nachman Norwood & Parrott's TVRD Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of Tvardi Therapeutics (TVRD) in Q4 2020, closing a stake of 4 shares — an estimated $2K sold.

Nachman Norwood & Parrott first reported a position in TVRD in Q3 2020 and held it in 1 quarter. The position peaked at $2K in Q3 2020. 156 funds tracked by Wall St. Rank hold TVRD as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining Tvardi Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 4 Tvardi Therapeutics shares in Q4 2020, an estimated $2K.
  • Nachman Norwood & Parrott first reported a position in Tvardi Therapeutics in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's Tvardi Therapeutics position peaked at $2K in Q3 2020.
  • 156 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.